Company intelligence / Profile preview
Krystal Biotech, Inc.
Pittsburgh, Pennsylvania, United Stateskrystalbio.gcs-web.com ↗
- Ownership
- Public · KRYS
- Development stage
- Commercial
01
Overview
Krystal Biotech has received FDA approval for VYJUVEK (beremagene geperpavec-svdt), the first redosable gene therapy for treating dystrophic epidermolysis bullosa. The company reported strong Q4 2024 results with revenues increasing 116% to $91.1 million and full-year revenues growing 473% to $290.5 million. VYJUVEK achieved a 95% gross margin in Q4 with over 510 reimbursement approvals in the U.S. The company also received European Commission approval for VYJUVEK in April 2025. Their KB707 oncology program showed a 27% objective response rate in lung cancer patients[6][9].
- Therapeutic areas
- PulmonologyOphthalmologyDermatologyOncologyRare Diseases
- Modalities
- Gene therapyRedosable gene therapyHSV-1-based vector technology
- Industry
- Biotech
02
Drug pipeline
14 assets13 more assets in the full pipeline.
Request access →03
Financials
- Market cap
- $10.2B
- Total revenue
- $119.2M
- Enterprise value
- $9.3B
Beyond the preview
Go deeper on Krystal Biotech, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Krystal Biotech, Inc..